Ratings Molina Healthcare, Inc.

Equities

MOH

US60855R1005

Delayed Nyse Other stock markets 03:59:41 2024-05-09 pm EDT			5-day change	1st Jan Change
349.7 ^USD	+1.53%		+3.10%	-3.11%

May. 03	Declaration of Voting Results by Molina Healthcare, Inc	CI
Apr. 30	TD Cowen Adjusts Price Target on Molina Healthcare to $412 From $453, Keeps Buy Rating	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The stock, which is currently worth 2024 to 0.43 times its sales, is clearly overvalued in comparison with peers.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company does not generate enough profits, which is an alarming weak point.
The company appears highly valued given the size of its balance sheet.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
MOLINA HEALTHCARE, INC.	-3.11%	20.18B	B-
UNITEDHEALTH GROUP INC.	-3.54%	463B	B-
CIGNA	+17.21%	98.67B	B-
CENTENE CORPORATION	+4.66%	40.48B	B-
HUMANA INC.	-26.95%	39.06B	A-
PROGYNY, INC.	-12.61%	3.09B	C+
ALIGNMENT HEALTHCARE, INC.	-19.74%	1.3B	B-
CLOVER HEALTH INVESTMENTS, CORP.	-10.02%	432M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes